Evidence map›Paper›PMID 40903311›Full record

ArticleEBioMedicine2025

A sensitive and specific non-invasive urine biomarker panel for prostate cancer detection.

Menglang Yuan, Marcio Covas Moschovas, Kandarp Joshi, Yohei Sanada, Roshane A Perera, Bongyong Lee, Rudramani Pokhrel, Jiri Polivka, Alexandra Miller, Ernest K Amankwah and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Menglang YuanDepartment of Neurosurgery and Oncology, Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, 1650 Orleans St., Baltimore, MD, 21231, USA; Johns Hopkins All Children's Hospital, 600 5th St. South, St. Petersburg, FL, 33701, USA.
Marcio Covas MoschovasAdventHealth Global Robotics Institute, 380 Celebration Place, Celebration, FL, 34747.
Kandarp JoshiDepartment of Neurosurgery and Oncology, Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, 1650 Orleans St., Baltimore, MD, 21231, USA; Johns Hopkins All Children's Hospital, 600 5th St. South, St. Petersburg, FL, 33701, USA.
Yohei SanadaDepartment of Neurosurgery and Oncology, Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, 1650 Orleans St., Baltimore, MD, 21231, USA; Johns Hopkins All Children's Hospital, 600 5th St. South, St. Petersburg, FL, 33701, USA.
Roshane A PereraAdventHealth Global Robotics Institute, 380 Celebration Place, Celebration, FL, 34747.
Bongyong LeeDepartment of Neurosurgery and Oncology, Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, 1650 Orleans St., Baltimore, MD, 21231, USA; Johns Hopkins All Children's Hospital, 600 5th St. South, St. Petersburg, FL, 33701, USA.
Rudramani PokhrelDepartment of Neurosurgery and Oncology, Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, 1650 Orleans St., Baltimore, MD, 21231, USA; Johns Hopkins All Children's Hospital, 600 5th St. South, St. Petersburg, FL, 33701, USA.
Jiri PolivkaDepartment of Histology and Embryology and Biomedical Center, Faculty of Medicine in Plzen, Charles University, Prague, Czech Republic.
Alexandra MillerJohns Hopkins All Children's Hospital, 600 5th St. South, St. Petersburg, FL, 33701, USA.
Ernest K AmankwahDepartment of Neurosurgery and Oncology, Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, 1650 Orleans St., Baltimore, MD, 21231, USA; Johns Hopkins All Children's Hospital, 600 5th St. South, St. Petersburg, FL, 33701, USA.
Ignacio Gonzalez-GomezJohns Hopkins All Children's Hospital, 600 5th St. South, St. Petersburg, FL, 33701, USA.
Naren NimmagaddaThe James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, 600 N Wolfe St., Baltimore, MD, 21287, USA.
Ezra BarabanDepartment of Pathology, Johns Hopkins University School of Medicine, 1800 Orleans St., Baltimore, MD, 21287, USA.
Anant JaiswalJohns Hopkins All Children's Hospital, 600 5th St. South, St. Petersburg, FL, 33701, USA.
Cuncong ZhongDepartment of Electrical Engineering and Computer Science, University of Kansas, 1520 W 15th St., Lawrence, KS, 66045, USA.
Inoel RiveraOrlando Health Medical Group Urology-Winter Park, 303 E Par St., Orlando, FL, 32804, USA.
Guru P SonpavdeAdventHealth Cancer Institute, 2501 N Orange Ave, Orlando, FL, 32804, USA.
Chetan BettegowdaDepartment of Neurosurgery and Oncology, Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, 1650 Orleans St., Baltimore, MD, 21231, USA.
Vipul PatelAdventHealth Global Robotics Institute, 380 Celebration Place, Celebration, FL, 34747.
Christian P PavlovichThe James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, 600 N Wolfe St., Baltimore, MD, 21287, USA.
Ranjan J PereraDepartment of Neurosurgery and Oncology, Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, 1650 Orleans St., Baltimore, MD, 21231, USA; Johns Hopkins All Children's Hospital, 600 5th St. South, St. Petersburg, FL, 33701, USA. Electronic address: jperera2@jh.edu.

Funding

Regulation, function, and the therapeutic potential of an oncogenic long noncoding RNA lnc-HLX-2-7 in group 3 medulloblastomasR01NS124668 · NINDS · JOHNS HOPKINS UNIVERSITY · PI Ranjan Joseph Perera · 2022 to 2026
$2.1M
NINDS NIH HHS R01 NS124668
6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is one of the leading causes of cancer death in men. While prostate-specific antigen (PSA) testing is widely used for screening, its diagnostic accuracy is limited, often failing to distinguish between benign and malignant prostate conditions, underscoring the need for novel biomarkers with improved diagnostic performance. This study aimed to identify and validate a panel of urinary RNA biomarkers with improved diagnostic accuracy for PCa.

methodsRNA-sequencing analysis of exfoliated cells in urine specimens identified 50 candidate RNAs. After initial qPCR testing in pooled urine, three biomarkers (TTC3, H4C5, EPCAM) with optimal specificity and sensitivity were selected as a biomarker panel. Diagnostic performance was evaluated in a case-control study divided into development (n = 243 participants) and validation (n = 646 participants) datasets. Biomarker expression was confirmed in tissue specimens, and the oncogenic function of TTC3 was assessed in vitro and in vivo.

findingsThe three-biomarker urine panel robustly identified PCa with an area under the curve (AUC) of 0.96 (95% CI: 0.94-0.98) compared to 0.83 (95% CI: 0.77-0.88) for urinary prostate cancer antigen 3 (PCA3) RNA in the development dataset and 0.92 (95% CI: 0.89-0.94) compared to 0.76 (95% CI: 0.72-0.80) for PCA3 in the validation dataset. Urine biomarkers were nearly eliminated post-prostatectomy and were confirmed to originate from prostate tissue at both the RNA and protein levels. The panel maintained high diagnostic accuracy of PSA-negative PCa cases and distinguished PCa from benign prostate conditions (BPH, prostatitis). Functional studies demonstrated that TTC3 depletion significantly suppressed in vitro and in vivo tumour growth.

interpretationThis urine-based biomarker panel offers a promising sensitive and specific noninvasive diagnostic for PCa with the potential to form the basis for laboratory-developed and in vitro diagnostic assays.

fundingThis study was supported by the International Prostate Cancer Foundation, JHU SKCCC (grant number P30CA006973), and Bankhead-Coley Cancer Research Program (grant number 24B16) to R. J. Perera and by the Maryland Innovation Initiative Grant to C. P. Pavlovich and R. J. Perera.

Indexed as

Biomarkers, TumorProstatic NeoplasmsAgedAnimalsAntigens, NeoplasmCase-Control StudiesCell Line, TumorHumansMaleMiddle AgedROC CurveAntigens, NeoplasmBiomarkers, Tumorprostate cancer antigen 3, humanBiomarkerLiquid biopsyProstate cancerUrine

Identifiers

PMID40903311
PMCPMC12789725

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.